⌕
Pfizer · PFE · NYSE
Tenet 50 · Mixed
Compare
$28.89+0.21%At closeTenet 50 · Mixed
$28.89+0.06 (+0.21%)
At close: Nov 13, 2026, 4:00 PM ET· NYSE · USD
$28.86
After hours: Nov 16, 2026, 7:53 PM ET

Pfizer (PFE) Earnings Forecast

Analysts expect Pfizer (PFE) to earn $3.05 a share in FY26, the average of 13 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$3.05
13 analysts
FY27 consensus EPS
$2.95
13 analysts · low $2.74, high $3.17
EPS revisions, 30 days
+2.9%
$2.96 to $3.05
Disagreement, FY26
11.0%
high to low, $2.92 to $3.26

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Pfizer to earn $2.31 a share in FY30, growing about −7% a year; 2 analysts publish an estimate for FY30.

Forward P/E · FY26E
9.5×
$28.89 (as of close, Nov 13, 2026) ÷ $3.05 consensus EPS
Coverage · FY26
13 · 18
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $3.05, up 2.6% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−1.2%+1.2%+3.6%FY27 +3.0%FY26 +2.6%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 2
FY2613 analysts▲ +2.9%$2.96 to $3.05▲ +2.6%$2.97 to $3.05▲ +3.0%$2.96 to $3.05
FY2713 analysts▲ +1.9%$2.90 to $2.95▲ +3.0%$2.87 to $2.95▲ +4.6%$2.82 to $2.95
Dec '2611 analysts▼ −2.6%$0.71 to $0.69▼ −3.2%$0.71 to $0.69▼ −3.2%$0.71 to $0.69
Mar '274 analysts21 of 30 days+3.0% so far21 of 90 days+3.0% so far▲ +3.0%$0.68 to $0.70

Contributors at both ends of the window: FY26 14 and 13. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

At 41.2 times earnings, which is what Pfizer trades at today, the FY27 consensus of $2.95 works out to $122 a share.

Consensus EPS · FY27
$2.95
13 analysts · low $2.74, high $3.17 · thin coverage
Multiple · today's trailing P/E
41.2×
$28.89 (as of close, Nov 13, 2026) ÷ $0.70, the last four reported quarters, including EPS computed by Tenet
×
Receipt · PFE · FY27Nov 13, 2026
Implied, a share
$122

Range on the low and high estimate: $113 to $131.

$113 low$131 high
2.95 × 41.2, to the dollar
Drag the multipleShaded: where Pfizer's P/E sat at each fiscal year end, FY07 to FY25. Each dot is one year.
10×20×30×40×50×60×
10-yr median 18.6×5-yr avg 27.9×today 41.2×$122 a share

Each point on the line is a multiple, and the flag is the price it implies for FY27. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

You are paying 9.5 times the FY26 consensus for earnings the Street expects to shrink about 10% a year to FY28. A falling number is not a growth rate, so the multiple is not divided by it here.Show today's multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY07 to FY25 · over 19 fiscal years. The mark is the median of the last 10.
41.2× today
9.4× low77.6× high
18.6× median
Forward 9.5× is a different measure, so it is not placed on a trailing record. Today's mark is the trailing 41.2×, on the same basis as every year behind it.

How much do analysts disagree?

For FY30, estimates run from $2.21 to $2.39 around an average of $2.31, drawn by 2 analysts.

FY26E13 analysts
$2.92 to $3.26 · 11.0%
FY27E13 analysts
$2.74 to $3.17 · 14.5%
FY28E6 analysts
$1.96 to $2.68 · 29.1%
FY29E3 analysts
$2.15 to $2.33 · 7.9%
FY30E2 analysts
$2.21 to $2.39 · 7.9%

The dashed line is FY25 filed $1.36, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average.

Is next quarter a high bar or an easy one?

Analysts expect Pfizer to earn $0.69 a share in the December quarter, the average of 11 estimates. Results are expected by Feb 2, 2027. Last quarter, which ended in September, Pfizer earned $0.62 a share. Analysts had expected $0.63, so it came in 2.0% lower.

0
$−0.29
$0.69high $0.83
low $0.61
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 11 analysts
Expected report
Feb 2, 2027
Expected by Feb 2. An estimate, not a date the company has set. Companies move it.
Revenue expected · December quarter
$17.2B
9 analysts, 16.8 to 17.5 in $B · 17.6 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. Last quarter's comparison is measured against the last estimate we hold for that quarter rather than the one from the night before the report, because the nearest estimate we hold for it was recorded after the company had already reported. For the March quarter, analysts expect $0.70 a share.

Does Pfizer usually beat or miss?

So far we have checked 4 quarters, of which 2 came in above the estimate we held. We add a quarter to this record each time Pfizer reports. The next report is expected by Feb 2, 2027.

We started recording estimates on Jul 2, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
+6.6%
Mar '24reaction
+6.1%
Jun '24left out · adjusted
+27.0%
Sep '24reaction
−1.4%
Dec '24left out · adjusted
Mar '25left out · adjusted
−12.1%
Jun '25reaction
+5.2%
−2.0%
Sep '25reaction
−1.5%
Dec '25left out · adjusted
Mar '26left out · adjusted
Jun '26left out · adjusted
Sep '26left out · adjusted
reportsFeb 2
Dec '26
Checked so far
4 quarters
one more every report
Beat expectations
2 of 4
full details on the Earnings tab
Share price reaction
Not held
we hold no measured reaction for the quarters we have checked
Typical gap vs estimate
+2.3%
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Pfizer on Jul 2, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact. Mar '24, Sep '24, Jun '25, Sep '25 are drawn hollow: we hold no estimate for those quarters recorded strictly before the report, so it is scored against the last estimate we hold rather than the night-before one.

The Street expects sales to grow −3.8% in FY27 and EPS −3.1%. The net margin moves from 27.7% to 27.8%, and the implied share count from about 5.73B to 5.73B, so these numbers assume the count stands still.Show the decomposition and the margin ladderHide the decomposition
FY27 EPS growth, in points
Revenue growth−3.8
Net margin change+0.6
Share count change+0.1
EPS growth−3.1
Legs are rounded to a tenth of a point and the largest remainder carries the difference, so they add to the total. Implied shares = consensus net income ÷ consensus EPS, a direction rather than a decimal.
13 analysts publish an EPS estimate for FY26 and 18 publish revenue. Coverage thins with distance: 2 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
1813
FY26E
1813
FY27E
226
FY28E
143
FY29E
112
FY30E
The FY26 panel held 15 analysts when our record of it began on Jul 2, 2026 and holds 13 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
4976103historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 18 revenue estimates for FY26, 11 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
0.062.875.67historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 13 EPS estimates for FY26, 2 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed62.6—1.36————as filed41.2×
FY26E63.161.6 to 63.8▲0.9%a3.052.92 to 3.26▲124.0%a30.617.55.7318 · 139.5×
FY27E60.759.4 to 62.7▼3.8%2.952.74 to 3.17▼3.1%29.316.95.7318 · 139.8×
FY28E55.251.7 to 58.1▼9.0%2.471.96 to 2.68n/cb25.314.25.7522 · 611.7×
FY29E53.751.9 to 55.2n/cb2.252.15 to 2.33n/cb23.012.85.6914 · 312.8×
FY30E54.352.5 to 55.8▲1.2%2.312.21 to 2.39▲2.6%23.113.15.6911 · 212.5×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 13 EPS estimates for FY26, 18 for revenue. Not investment advice.

What do analysts expect Pfizer to earn in FY26?

Analysts expect Pfizer to earn $3.05 a share in FY26, the average of 13 estimates as of Nov 13, 2026.

What is Pfizer's earnings forecast for FY27?

The FY27 consensus for Pfizer is $2.95 a share from 13 analysts, with a low of $2.74 and a high of $3.17, as of Nov 13, 2026.

Have analysts raised Pfizer's earnings estimates?

Pfizer's FY26 EPS consensus rose 2.6% in 91 days, from $2.97 to $3.05, as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.